Medifron DBT Co. Ltd (065650) - Total Liabilities

Latest as of September 2025: ₩86.61 Billion KRW ≈ $58.70 Million USD

Based on the latest financial reports, Medifron DBT Co. Ltd (065650) has total liabilities worth ₩86.61 Billion KRW (≈ $58.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Medifron DBT Co. Ltd to assess how effectively this company generates cash.

Medifron DBT Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how Medifron DBT Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 065650 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Medifron DBT Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Medifron DBT Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Genus PLC LSE:GNS	UK	GBX423.00 Million
Javelin Minerals Ltd AU:JAV	Australia	AU$1.37 Million
Prajay Engineers Syndicate Limited NSE:PRAENG	India	Rs3.31 Billion
NexgenRX Inc. V:NXG	Canada	CA$30.91 Million
RONSHINE CH.HLD.HD-00001 F:1R7	Germany	€92.71 Billion
MK Trend Co. Ltd. KO:069640	Korea	₩255.92 Billion
CLEAN TEQ WATER LTD F:9NK	Germany	€8.37 Million
Argha Karya Prima Ind Tbk JK:AKPI	Indonesia	Rp1.90 Trillion

Liability Composition Analysis (2014–2024)

This chart breaks down Medifron DBT Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 065650 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.01	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.40	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.76	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Medifron DBT Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Medifron DBT Co. Ltd (2014–2024)

The table below shows the annual total liabilities of Medifron DBT Co. Ltd from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩42.92 Billion ≈ $29.08 Million	+127.15%
2023-12-31	₩18.89 Billion ≈ $12.80 Million	-23.39%
2022-12-31	₩24.66 Billion ≈ $16.71 Million	+262.30%
2021-12-31	₩6.81 Billion ≈ $4.61 Million	-64.84%
2020-12-31	₩19.36 Billion ≈ $13.12 Million	+994.02%
2019-12-31	₩1.77 Billion ≈ $1.20 Million	-25.45%
2018-12-31	₩2.37 Billion ≈ $1.61 Million	+58.92%
2017-12-31	₩1.49 Billion ≈ $1.01 Million	-31.47%
2016-12-31	₩2.18 Billion ≈ $1.48 Million	-69.04%
2015-12-31	₩7.04 Billion ≈ $4.77 Million	+356.92%
2014-12-31	₩1.54 Billion ≈ $1.04 Million	--

About Medifron DBT Co. Ltd

KQ:065650 Korea Biotechnology

Market Cap

$19.03 Million

₩28.08 Billion KRW

Market Cap Rank

#25173 Global

#1873 in Korea

Share Price

₩2110.00

Change (1 day)

+10.18%

52-Week Range

₩210.00 - ₩6090.00

All Time High

₩8800.00